Breaking News
November 14, 2018 - Health Tip: Limit Fat, Sugar and Salt in Your Child’s Diet
November 14, 2018 - CA 19-9 Blood Test (Pancreatic Cancer): MedlinePlus Lab Test Information
November 14, 2018 - Old drug could have new use helping sick premature babies
November 14, 2018 - Surgery, not antibiotics, should remain first-line treatment for appendicitis | News Center
November 14, 2018 - Researchers to develop sports-specific classification system for blind football
November 14, 2018 - Preschool children show awake responses to naptime nonsense words
November 14, 2018 - Survey shows negative effect of vulvovaginal atrophy symptoms on quality of life for women
November 14, 2018 - Study sheds light on mechanisms that prevent autoimmune attack
November 14, 2018 - Sleep quality found to be worse for women who undergo surgical menopause
November 14, 2018 - New study provides deeper insight into chromosome segregation during mitosis
November 14, 2018 - Inhibition of one protein clears toxic clumps seen in Parkinson’s disease, study finds
November 14, 2018 - Appendix removal is linked to lower risk of Parkinson’s
November 14, 2018 - Lifting weights for less than an hour a week may reduce cardiovascular disease risk
November 14, 2018 - Pulmonary rehabilitation rarely received by hospitalized COPD patients despite health benefits
November 14, 2018 - New anti-HER2 drug shows promising anti-tumor activity in gullet, stomach and bowel cancers
November 14, 2018 - Regular head circumference assessment of preterm babies can help identify long-term IQ problems
November 14, 2018 - Brigham investigators examine opioid use among Massachusetts adolescents, prescription trends
November 14, 2018 - Study defines biomarker in response to treatment of castration-resistant prostate cancer
November 14, 2018 - Study identifies potential therapeutic strategy for patients with clear cell renal cancer
November 14, 2018 - Bausch Health Announces U.S. Launch of Bryhali (halobetasol propionate) Lotion, 0.01%, for Plaque Psoriasis In Adults
November 14, 2018 - Alpha Fetoprotein (AFP) Tumor Marker Test: MedlinePlus Lab Test Information
November 14, 2018 - Researchers evaluate controversial treatment for Parkinson’s disease psychosis
November 14, 2018 - AI could help veterinarians code their notes
November 14, 2018 - Pre-schoolers with autism thrive in mainstream classroom settings
November 14, 2018 - Individual and work-related factors may help promote hospital physician engagement, finds study
November 14, 2018 - Complementary and alternative medicine is widely used by general population in England
November 14, 2018 - Study reveals link between tobacco availability and smoking during pregnancy
November 14, 2018 - Purdue researchers develop translucent base for silicon patches to deliver exact doses of biomolecules
November 14, 2018 - New technology based on moths and magnets could help treat genetic diseases
November 14, 2018 - Concussion-Related Biomarkers Vary Based on Sex, Race
November 14, 2018 - One more year of high school may shape waistlines later in life
November 14, 2018 - Dissecting high drug costs – Scope
November 14, 2018 - Study shows novel strategy to reduce breast cancer bone metastasis
November 14, 2018 - Empowering the NHS through Industry Partnerships
November 14, 2018 - One size does not fit all in obesity treatment, study finds
November 14, 2018 - Seeking ways to prevent ‘secondary cataracts’
November 14, 2018 - Change Within the Eye May Be Early Warning for Macular Degeneration
November 14, 2018 - Study of 500,000 people clarifies the risks of obesity
November 14, 2018 - Ultrasound releases drug to alter activity in targeted brain areas in rats | News Center
November 14, 2018 - Umass Amherst researchers battle against youth suicide in rural Alaska Native communities
November 14, 2018 - Cancer stem cells depend on amino acid metabolism, and it’s proving to be their Achilles’ heel
November 14, 2018 - Epigenetic link found between prenatal exposure to maternal smoking and offspring’s cardio-metabolic health
November 14, 2018 - Meditation, music may change biomarkers of cellular aging and Alzheimer’s disease in older adults
November 14, 2018 - Multidisciplinaryresearch teams selected to study age-related brain disorders
November 14, 2018 - The Current issue of “The view from here” is concerned with Informatics
November 14, 2018 - Researchers identify tool to help transgender women have a more authentic voice
November 14, 2018 - Four faculty members appointed to endowed professorships | News Center
November 13, 2018 - Research finds strongest evidence yet that obesity causes depression
November 13, 2018 - Researchers compare stools of breastfed and formula-fed infants
November 13, 2018 - Entasis Therapeutics Announces Zoliflodacin Phase 2 Results Published in The New England Journal of Medicine
November 13, 2018 - Gene changes driving myopia reveal new focus for drug development
November 13, 2018 - $6 million grant to support study of preeclampsia, atherosclerosis links | News Center
November 13, 2018 - Beneficial gut microbes metabolize high-fiber diet to improve heart health in mouse model
November 13, 2018 - Excessive use of social media through visual postings linked to increase in narcissistic traits
November 13, 2018 - Study finds why obesity both fuels cancer growth and helps immunotherapy to kill tumors
November 13, 2018 - Women prefer and invest more in daughters, while men favor sons
November 13, 2018 - With hospitalization losing favor, judges order outpatient mental health treatment
November 13, 2018 - Transgenic rat model may provide new insights into cerebral amyloid angiopathy
November 13, 2018 - Study identifies factors tied to greater risk of advanced liver disease in cystic fibrosis patients
November 13, 2018 - Risk of blindness among premature babies with low levels of blood platelets
November 13, 2018 - A new strategy for combatting antibiotic-resistant infections
November 13, 2018 - Study aims to find which outreach method is more effective at improving cancer screening rates
November 13, 2018 - Insufficient sleep duration linked with unhealthy lifestyle profile among children
November 13, 2018 - IIASA researchers introduce new, simple measure for human wellbeing
November 13, 2018 - Magnetic nanosprings used as targeted drug delivery agents for anticancer therapy
November 13, 2018 - Scientists examine FCMs containing silver nanoparticles
November 13, 2018 - Failed DNA repair triggers chromosomal chaos
November 13, 2018 - Study shows new emerging role of osteopontin in HCV-related hepatocellular carcinoma
November 13, 2018 - Food insecurity during pregnancy linked to severity of neonatal abstinence syndrome
November 13, 2018 - Majority of Americans are concerned about health threat posed by antibiotic resistance
November 13, 2018 - Addition of Elotuzumab Ups PFS in Refractory Multiple Myeloma
November 13, 2018 - Study finds women with pregnancy-related nausea, vomiting use marijuana more
November 13, 2018 - Lethal heart rhythm more likely to be found in patients with common heart failure
November 13, 2018 - Study provides new clues to origin and development of multiple sclerosis
November 13, 2018 - Climate change could pose threat to male fertility
November 13, 2018 - Researchers discover how mitochondria deploy a powerful punch against disease-causing bacteria
November 13, 2018 - AHA: Traumatic Childhood Could Increase Heart Disease Risk in Adulthood
November 13, 2018 - Feeling the Burn? | NIH News in Health
November 13, 2018 - Women’s birth canals in Kenya, Korea, Kansas not the same: study
November 13, 2018 - Fecal microbiota transplantation effective against ICI-associated colitis
Autoinjected Secukinumab a Hit in Psoriatic Arthritis

Autoinjected Secukinumab a Hit in Psoriatic Arthritis

image_pdfDownload PDFimage_print

Action Points

  • Note that this randomized study found that the Il-17a inhibitor secukinumab was efficacious in improving symptoms among patients with psoriatic arthritis.
  • Be aware that the medication fared best among those who had not previously been treated with an anti-TNF agent. Higher doses may be needed for those who were previously exposed.

The interleukin (IL)-17A inhibitor secukinumab (Cosentyx) provided durable benefits in the treatment of psoriatic arthritis, and patient satisfaction with self-administration using an autoinjector was high, researchers found.

At week 24 in a phase III trial known as FUTURE 3, improvements of at least 20% on the criteria of the American College of Rheumatology (ACR20) were seen in 48.2% of patients receiving 300 mg of secukinumab every 4 weeks and in 42% of those receiving 150 mg, compared with 16.1% of those given placebo (P<0.0001), according to Peter Nash, MD, of the University of Queensland in Brisbane, Australia, and colleagues.

Week 24 was the end of the placebo-controlled phase of the study. By week 52, when all patients were receiving the active treatment, ACR20 response rates rose to 58.3% and 47.1% in the 300- and 150-mg groups, respectively.

And at least 88% of patients said that they were satisfied or very satisfied with the autoinjector, finding it easy or very easy to use, the researchers reported in Arthritis Research & Therapy.

The efficacy findings confirm what has previously been seen in other phase III trials of subcutaneous secukinumab. For example, in a study known as FUTURE 1, published in 2015 in the New England Journal of Medicine, ACR20 responses at week 24 were observed in 50% of patients receiving 150 mg monthly and in 50.5% of those receiving 75 mg. In FUTURE 2, published the same year in The Lancet, 54% of patients receiving 300 mg had ACR20 responses at week 24, as did 51% of those given 150 mg.

FUTURE 3 is an ongoing randomized trial being conducted at 74 centers worldwide. Participants have active disease, defined as at least three tender and swollen joints, and could have previously received up to three tumor necrosis factor (TNF) inhibitors.

A total of 414 patients were enrolled. Mean age was 50, slightly more than half were women, and more than 90% were white. Mean time since the diagnosis of psoriatic arthritis ranged from 6.6 to 8.3 years, and one-third had previously received a TNF inhibitor. Mean number of tender and swollen joints were 21 and 10, respectively.

Almost half were using methotrexate at baseline.

In general, patients who were anti-TNF naive fared better. At week 24, the ACR20 and ACR50 responses among patients who were anti-TNF naive were 51.6% and 45.7% in the 300 mg and 150 mg groups, respectively, while in patients who had previously had an inadequate response to anti-TNF treatment, the response rates in the two dosage groups were 40.9% and 34.1%.

The greater responses seen with the higher dose among patients with previous anti-TNF exposure suggests that the 300 mg dose is appropriate for these refractory patients, the authors indicated.

On the Psoriasis Area and Severity Index (PASI), improvements of 75% were seen in 61.3% and 55.9% of the 300- and 150-mg groups at week 24, compared with 11.9% of the placebo group. At week 52, PASI75 responses were seen in 74.2% of the 300-mg group and in 60.3% of the 150-mg group.

On the Health Assessment Questionnaire-Disability Index (HAQ-DI) changes from baseline at week 24 were -0.38 in the 300-mg group and -0.27 in the 150-mg group compared with -0.17 in the placebo group, and mean changes in pain scores were -18.23 and-12.46 versus -3.75. At week 52, changes from baseline on the HAQ-DI were -0.43 and -0.30 in the 300 mg and 150 mg groups, while changes in pain scores were -20.3 and -11.8.

During the 52 weeks, the incidence rates of adverse events were 194.9 and 192.5 per 100 patient-years, while the rates of serious adverse events were 8.8 and 10.2 per 100. Two deaths occurred — one pancreatic cancer and one small cell lung cancer.

Candida infections were an adverse event of special interest, because IL-17 plays a crucial role in mucocutaneous defense against fungal and bacterial infections. Oral candidiasis was reported in three patients in the 300-mg group and five patients in the 150-mg group, and two patients in each dose group experienced vulvovaginal candidiasis. Patients on secukinumab should be observed closely for Candida infections, the researchers noted.

Neutropenia developed in two patients in the 150-mg group and one patient in the 300-mg group.

“In summary, self-administration of subcutaneous secukinumab provided sustained improvements at 52 weeks across multiple clinical domains in patients with active psoriatic arthritis,” Nash and colleagues concluded, adding that patients were satisfied with the autoinjector device.

A limitation of the study was the lack of a placebo control after week 24.

The study was funded by Novartis Pharma.

The authors reported financial relationships with Novartis, AbbVie, Roche, Pfizer, Bristol-Myers Squibb, Janssen, Celgene, Crescendo Bioscience, Genentech, Eli Lilly, Merck, UCB, and Amgen. Several are employees of Novartis.

2018-03-16T15:30:00-0400

Tagged with:

About author

Related Articles